Carcinoma, Non-Small-Cell Lung: all 6,645 studies
Page 52 of 67. Open to participants first (1,667), then studies with results posted, then the rest; newest registration first within each.
- VARGADO - Vargatef in 2nd-line Therapy of Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02392455
- Study of Anlotinib in Patients With Advanced Non-small Cell Lung Cancer（ALTER0303）CompletedNCT02388919Phase 2/3
- A Study of rSIFN-co in Subjects With Advanced Solid TumorsCompletedNCT02387307Phase 1
- Study on Potential Biomarkers Associated With Clinical Phenotype of EGFR-TKIs in No-small Cell Lung Cancer in ChinaStatus unknownNCT02381808
- Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory CancerCompletedNCT02381314Phase 1
- The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung CancerCompletedNCT02380196
- Safety Study of SEA-CD40 in Cancer PatientsTerminatedNCT02376699Phase 1
- A Phase I Study of Safety and Pharmacokinetics of Volitinib in Combination With Gefitinib in EGFR(+) NSCLCCompletedNCT02374645Phase 1
- A Study to Isolate and Test Circulating Tumor Cells Using the ClearCell® FX EP+ SystemCompletedNCT02370303
- Combined Effect of Natural Killer Cell and Doublet Chemotherapy in Advanced NSCLC as the 1st Line TreatmentStatus unknownNCT02370017Phase 2
- MesomiR 1: A Phase I Study of TargomiRs as 2nd or 3rd Line Treatment for Patients With Recurrent MPM and NSCLCCompletedNCT02369198Phase 1
- T790M Mutation Positive 2nd Line STandard of cAre RegistryWithdrawnNCT02368990
- Hypofractionated Accelerated Radiotherapy With Concomitant Chemotherapy for NSCLCStatus unknownNCT02367443Phase 1/2
- A Study to Evaluate the Efficacy of Anti-emetic Drug Upon the Combination Chemotherapy for Non-small Cell Lung CancerCompletedNCT02364804
- A Study of Famitinib Plus Docetaxel in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)CompletedNCT02364362Phase 1
- Surgical Treatment of Elderly Patients With cT1N0M0 Non-small Cell Lung Cancer Comparison Between Sublobar Resection and LobectomyStatus unknownNCT02360761Phase 3
- A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)SuspendedNCT02356991Phase 2
- Itacitinib in Combination With Erlotinib in Non Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Activating MutationsWithdrawnNCT02355431Phase 2
- Concurrent EGFR-TKIs and Thoracic Radiation Therapy in Active EGFR Mutation for 1st Line Treatment of Stage IV NSCLCTerminatedNCT02353741Phase 2
- Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001)TerminatedNCT02346955Phase 1
- Pacritinib in Patients With Endothelial Growth Factor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC) After EGFR Tyrosine Kinase Inhibitor (TKI)TerminatedNCT02342353Phase 1
- A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47CompletedNCT02340208Phase 1/2
- Powered Surgical Stapler in VATS Lung Resection Procedures in ChinaCompletedNCT02338583
- Comparator-Controlled Study for EGFR(+) Patients With Multiple BMs From NSCLC (BROKE) (EGFR-epidermal Growth Factor Receptor;BM-brain Metastases)Status unknownNCT02338011Phase 2/3
- Evaluation of Gender Differences on the Psychosocial and Economic Impact in Patients With Advanced Non-small Cell Lung CancerTerminatedNCT02336061
- Study of Apatinib as 3rd/4th Line Treatment in Patients With Advanced Non-Squamous Non-small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor (EGFR)Status unknownNCT02332512Phase 3
- Safety, Pharmacokinetic and Preliminary Efficacy Study of AC0010 in Patients With EGFR T790M Positive NSCLCStatus unknownNCT02330367Phase 1/2
- Induction Therapy With Intercalated Tyrosine Kinase Inhibitor (TKI) and Chemotherapy in NSCLC With Activating Epidermal Growth Factor Receptor (EGFR) Mutation in Stages II-IIIBTerminatedNCT02326285Phase 2/3
- PET/CT Imaging of Angiogenesis in Lung or Head and Neck Cancers Prior or During Chemotherapy With Antiangiogenic AgentsTerminatedNCT02325349Phase 2
- An epidemiOlogy Study to deteRmine the Prevalence of EGFR (Epidermal Growth Factor Receptor) muTations in RUSsian Patients With Advanced NSCLC (Non-Small Cell Lung Cancer).CompletedNCT02321046
- Feasibility Study of SBRT Plus Chemotherapy for Non-Small Cell Lung CarcinomaTerminatedNCT02319889Early Phase 1
- GEfitinib Plus viNOrelbine in Advanced EGFR Mutated NSCLC. GENOA TrialStatus unknownNCT02319577Phase 2
- Immune Boost In Non-Small Cell Lung CancerCompletedNCT02319408Not applicable
- Deciphering Antitumour Response and Resistance With INtratumour HeterogeneityCompletedNCT02314481Phase 2
- Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast CancerCompletedNCT02309177Phase 1
- Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLCTerminatedNCT02299765Phase 4
- Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)CompletedNCT02299505Phase 1
- A Study of Atezolizumab in Combination With Epacadostat in Subjects With Previously Treated Stage IIIB or Stage IV Non-Small Cell Lung Cancer and Previously Treated Stage IV Urothelial CarcinomaTerminatedNCT02298153Phase 1
- Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.CompletedNCT02292550Phase 1
- Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung CancerStatus unknownNCT02288026
- A Study of BIND-014 (Docetaxel Nanoparticles for Injectable Suspension) as Second-line Therapy for Patients With KRAS Positive or Squamous Cell Non-Small Cell Lung CancerCompletedNCT02283320Phase 2
- Expression and Sequence of Calcium Channels in Non-small Cell Lung Carcinoma (NSCLC)Status unknownNCT02283021
- Personalized Adaptive Radiation Therapy With Individualized Systemic Targeted Therapy (PARTIST) for Locally Advanced, Non-small Cell Lung Cancer With Genomic Driver MutationsWithdrawnNCT02277457Early Phase 1
- Cisplatin/Irinotecan With Concurrent Radiation for Inoperable NSCLCTerminatedNCT02275806Phase 2
- Safety, Tolerability, Pharmacokinetics and Anti-tumour Activity of AC0010 in Advanced Non Small Cell Lung CancerStatus unknownNCT02274337Phase 1/2
- Evaluation of FLT-PET and DWI-MRI in Patients With NSCLC Treated With a Platinum-based Doublet as Preoperative ChemoStatus unknownNCT02273271Not applicable
- Study of Chemotherapy Plus Icotinib to Treat EGFR Mutation-positive Non-small-cell Lung CancerStatus unknownNCT02272127Phase 2
- Effect of Symptom Management on Inflammation and Survival in Metastatic Lung CancerCompletedNCT02271581
- Expanded Access Study of Alectinib for Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC) After Disease Progression on or Intolerance to Prior ALK Tyrosine Kinase Inhibitor TherapyNo longer availableNCT02271139
- Efficacy and Safety of Momelotinib Combined With Trametinib in Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in PhaseTerminatedNCT02258607Phase 1
- Study of Itacitinib in Combination With Docetaxel in Subjects With Non-Small Cell Lung CancerTerminatedNCT02257619Phase 2
- Exploratory Study of QBKPN SSI in Non-Small Cell Lung CancerCompletedNCT02256852Phase 2
- Phase I Hypofractionated Stereotactic Boost (Radiotherapy) for Non-Small Cell Lung CancerTerminatedNCT02252796Phase 1
- Study of EGFR-TKI to Asymptomatic Brain Metastases of NSCLCStatus unknownNCT02250846Phase 2
- Stereotactic Radiosurgery Followed by Wedge Resection in Treating Patients With Early Stage Peripheral Non-small Cell Lung CancerWithdrawnNCT02250378Not applicable
- An International Study on the Use of PET/CT in Radiotherapy Planning in Low and Middle Income CountriesStatus unknownNCT02247713
- Circulating Tumor DNA in Predicting Outcomes in Patients With Stage IV Head and Neck Cancer or Stage III-IV Non-small Cell Lung CancerCompletedNCT02245100
- Palliative Care Intervention in Improving Symptom Control and Quality of Life in Patients With Stage II-IV Non-small Cell Lung Cancer and Their Family CaregiversCompletedNCT02243748Not applicable
- Study to Evaluate Real-world Pharmacoeconomics of Crizotinib in NSCLC PatientsTerminatedNCT02228421
- Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung CancerCompletedNCT02228369Phase 1
- Paclitaxel-trastuzumab in EGFR-mutated NSCLC PatientsStatus unknownNCT02226757Phase 2
- Cisplatin, Docetaxel, and Nintedanib Before Surgery in Treating Patients With Previously Untreated Stage IB-IIIA Non-small Cell Lung CancerCompletedNCT02225405Phase 1
- Risk-adapted Stereotactic Body Radiotherapy for Early Non-Small Cell Lung Cancer Using the VERO Stereotactic Body Radio Therapy SystemStatus unknownNCT02224547Phase 2
- Clinical Observation of S1 Capsule for Stage Ⅱ-ⅢA Non-small Cell Lung Cancer After Complete ResectionStatus unknownNCT02223611Phase 2
- Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic MalignanciesCompletedNCT02223052Phase 1
- Icotinib With Concurrent Radiotherapy Versus Chemotherapy With Concurrent Radiotherapy in Non-small Cell Lung CancerStatus unknownNCT02215356Phase 2
- Dose Escalation Study of BI 2536 With Pemetrexed in Previously Treated Patients With Non-small-cell Lung CancerCompletedNCT02211833Phase 1
- Single Dose Escalation Study of 131I-Sibrotuzumab in Patients With Advanced or Metastatic Non-small Cell Lung CancerTerminatedNCT02209727Phase 1
- Erlotinib and Momelotinib for the Treatment of Epidermal Growth Factor Receptor (EGFR) Mutated EGFR Tyrosine Kinase Inhibitor (TKI) Naive Metastatic Non-Small Cell Lung Cancer (NSCLC)TerminatedNCT02206763Phase 1
- Stereotactic Body Radiation Therapy in Treating Patients With Metastatic Breast Cancer, Non-small Cell Lung Cancer, or Prostate CancerCompletedNCT02206334Phase 1
- A Study Evaluating RO5479599 in Combination With Carboplatin and Paclitaxel in Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC) of Squamous HistologyTerminatedNCT02204345Phase 1/2
- Biodistribution Study With 186 Re-labelled Humanised Monoclonal Antibody BIWA 4 in Patients With Non-small Cell Lung CancerCompletedNCT02204059Phase 1
- Study of Changes of Lymphocyte Subsets in Chemotherapy Course of Patients With Non-small Cell Lung CancerStatus unknownNCT02202655
- Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02201992Phase 3
- The Safety and Efficacy of Pemetrexed Rechallenge With BevacizumabTerminatedNCT02200354Phase 2
- Chemotherapy Combined With Yangzhengxiaoji Capsule in Patients With Advanced Non-Small Cell Lung CancerStatus unknownNCT02195453Phase 4
- Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)Active, not recruitingNCT02194738Not applicable
- Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLCStatus unknownNCT02194556Phase 4
- Erlotinib Hydrochloride in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Completely Removed by Surgery (An ALCHEMIST Treatment Trial)Active, not recruitingNCT02193282Phase 3
- An Open Study of ASP8273 in Patients With Non-Small-Cell Lung Cancer (NSCLC) Who Have Epidermal Growth Factor Receptor (EGFR) MutationsTerminatedNCT02192697Phase 1/2
- Phase II Clinical Study of Intermittent High Dose of Icotinib in Combination With Docetaxel to Treat Lung CancerStatus unknownNCT02191059Phase 2
- Postoperative Radiotherapy of Non-small Cell Lung Cancer: Accelerated vs. Conventional FractionationCompletedNCT02189967Not applicable
- Safety & Efficacy Study of EGF Cancer Vaccine to Treat Stage IV Biomarker Positive, Wild Type EGF-R NSCLC PatientsTerminatedNCT02187367Phase 3
- Deciphering Afatinib Response and Resistance With INtratumour HeterogeneityCompletedNCT02183883Phase 2
- A Dose Escalation Study of BIBF 1120 Together With Paclitaxel and Carboplatin in Patients With Advanced Stage Non-small-cell Lung CancerCompletedNCT02182232Phase 1
- Dose Escalation of BIBF 1120 Combined With Pemetrexed in Advanced Non Small Cell Lung CancerCompletedNCT02182102Phase 1
- Efficacy and Safety of Oral Treatment With BIBF 1120 ES in Advanced Non-small-cell Lung CancerCompletedNCT02182050Phase 2
- Docetaxel Plus Bevacizumab for Elderly Patients With Stage IV NSCLCTerminatedNCT02179567Phase 2
- A Multicenter Randomized Phase III Study Comparing Second-line Treatment With Chemotherapy Associated or Not to Erlotinib in NSCLC Patients With Secondary Resistance to TKI-EGFRTerminatedNCT02178397Phase 3
- Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung CancerActive, not recruitingNCT02178163Not applicable
- Maintenance Low Dose Oral Navelbine In Patients With Non Small Cell Lung Cancer - MA.NI.LA TrialCompletedNCT02176369Phase 2
- Carboplatin Plus Gemcitabine for Elderly Patients With Stage IV NSCLCCompletedNCT02175381Phase 1/2
- Hypofractionated Proton Beam Radiation Therapy, Paclitaxel, and Carboplatin in Treating Patients With Stage II-III Non-Small Cell Lung CancerCompletedNCT02172846Phase 1
- The Oncopanel Pilot (TOP) StudyCompletedNCT02171286
- Molecular Diagnosis on Circulating Tumor DNA of Non-Small Cell Lung CancerCompletedNCT02169349
- Ethaselen for the Treatment of Thioredoxin Reductase High Expression Advanced Non-small Cell Lung CancersCompletedNCT02166242Phase 1
- Therapeutic Strategies in Patients With Non-squamous Non-small Cell Lung Cancer With Brain MetastasesTerminatedNCT02162537Phase 3
- Aprepitant for Chemotherapy Induced Nausea and Vomiting in Chinese Advanced Non-small Cell Lung CancersCompletedNCT02161991Phase 3
- Prognostic and Dynamic Change of CTC Enumeration in Advanced NSCLC With Chemotherapy and Targeted TherapyStatus unknownNCT02155426
- EF5 in Measuring Tumor Hypoxia in Patients With Stage I-III Non-Small Cell Lung CancerCompletedNCT02154399Phase 2